Comprehensive Stock Comparison
Compare PMGC Holdings Inc. (ELAB) vs Evogene Ltd. (EVGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  EVGN | 50.9% revenue growth vs ELAB's 44.1% |
| Quality / Margins | EVGN | -52.3% net margin vs ELAB's -253.1% |
| Stability / Safety | EVGN | Beta 0.54 vs ELAB's 1.74 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | EVGN | -40.6% vs ELAB's -96.5% |
| Efficiency (ROA) | EVGN | -10.5% ROA vs ELAB's -44.6%, ROIC -102.4% vs -82.7% |
Who Each Stock Is For
Income & stability
EVGNbeta 0.54
Growth exposure
ELABRev growth 44.1%, EPS growth 86.0%, 3Y rev CAGR 13.4%
Long-term compounding (10Y)
EVGN-98.8% 10Y total return vs ELAB's -100.0%
Sleep-well-at-night portfolio
EVGNLower volatility, beta 0.54, Low D/E 86.8%, current ratio 1.15x
Defensive / Recession hedge
EVGNBeta 0.54, current ratio 1.15x
Business Model
What each company does and how it makes money
PMGC Holdings is a biopharmaceutical company developing novel aesthetic medicines and therapeutic products, with a focus on engineered probiotics for muscle preservation during weight loss treatments. It generates revenue primarily through research and development activities, investment operations, and potential future commercialization of its lead product EL-22 — a first-in-class probiotic targeting obesity-related muscle loss. The company's competitive advantage lies in its proprietary engineered probiotic technology platform addressing an emerging need in the rapidly growing GLP-1 weight loss market.
Evogene is a computational biology company that uses its proprietary AI-powered platform to discover and develop products across agriculture, human health, and industrial applications. It generates revenue through research collaborations, licensing agreements, and milestone payments from partners—primarily in agriculture (~70% of focus) and human health (~30%). The company's key advantage is its Computational Predictive Biology platform, which leverages big data and machine learning to accelerate product discovery in life sciences with higher precision than traditional methods.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ELAB 3EVGN 2ELAB4/6 metricsELAB2/3 metricsELAB5/8 metricsEVGN6/6 metricsEVGN2/2 metricsELAB leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). EVGN leads in 2 (Total Returns, Risk & Volatility).
Financial Metrics (TTM)
EVGN and ELAB operate at a comparable scale, with $5M and -$1M in trailing revenue. Profitability is closely matched — net margins range from -52.3% (EVGN) to -2.5% (ELAB). On growth, ELAB holds the edge at -45.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| RevenueTrailing 12 months | -$1M | $5M |
| EBITDAEarnings before interest/tax | -$4M | -$13M |
| Net IncomeAfter-tax profit | -$7M | -$3M |
| Free Cash FlowCash after capex | -$7M | -$17M |
| Gross MarginGross profit ÷ Revenue | +72.8% | +16.1% |
| Operating MarginEBIT ÷ Revenue | -75.7% | -2.8% |
| Net MarginNet income ÷ Revenue | -2.5% | -52.3% |
| FCF MarginFCF ÷ Revenue | -2.2% | -3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -45.8% | -82.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | +133.6% |
Valuation Metrics
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| Market CapShares × price | $23,875 | $7M |
| Enterprise ValueMkt cap + debt − cash | -$4M | $5M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | 0.86x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.32x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
EVGN delivers a -15.9% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-78 for ELAB. On the Piotroski fundamental quality scale (0–9), ELAB scores 4/9 vs EVGN's 3/9, reflecting mixed financial health.
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| ROE (TTM)Return on equity | -78.4% | -15.9% |
| ROA (TTM)Return on assets | -44.6% | -10.5% |
| ROICReturn on invested capital | -82.7% | -102.4% |
| ROCEReturn on capital employed | -33.7% | -66.5% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | — | 0.87x |
| Net DebtTotal debt minus cash | -$4M | -$2M |
| Cash & Equiv.Liquid assets | $4M | $15M |
| Total DebtShort + long-term debt | $0 | $13M |
| Interest CoverageEBIT ÷ Interest expense | -17.68x | -4.42x |
Total Returns (with DRIP)
A $10,000 investment in EVGN five years ago would be worth $183 today (with dividends reinvested), compared to $1 for ELAB. Over the past 12 months, EVGN leads with a -40.6% total return vs ELAB's -96.5%. The 3-year compound annual growth rate (CAGR) favors EVGN at -51.8% vs ELAB's -96.0% — a key indicator of consistent wealth creation.
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| YTD ReturnYear-to-date | -26.1% | -25.8% |
| 1-Year ReturnPast 12 months | -96.5% | -40.6% |
| 3-Year ReturnCumulative with dividends | -100.0% | -88.8% |
| 5-Year ReturnCumulative with dividends | -100.0% | -98.2% |
| 10-Year ReturnCumulative with dividends | -100.0% | -98.8% |
| CAGR (3Y)Annualised 3-year return | -96.0% | -51.8% |
Risk & Volatility
EVGN is the less volatile stock with a 0.54 beta — it tends to amplify market swings less than ELAB's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EVGN currently trades 34.6% from its 52-week high vs ELAB's 3.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 0.54x |
| 52-Week HighHighest price in past year | $30.50 | $2.42 |
| 52-Week LowLowest price in past year | $1.01 | $0.81 |
| % of 52W HighCurrent price vs 52-week peak | +3.4% | +34.6% |
| RSI (14)Momentum oscillator 0–100 | 16.2 | 36.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 547K |
Analyst Outlook
| Metric | ELABPMGC Holdings Inc. | EVGNEvogene Ltd. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Mar 26 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 100 | 0.01 | -100.0% |
| Evogene Ltd. (EVGN) | 100 | 12.5 | -87.5% |
Evogene Ltd. (EVGN) returned -98% over 5 years vs PMGC Holdings Inc. (ELAB)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $0.00 | $2M | — |
| Evogene Ltd. (EVGN) | $11M | $9M | -23.5% |
Evogene Ltd.'s revenue grew from $11M (2015) to $9M (2024) — a -2.9% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -948.9% | -2.5% | +99.7% |
| Evogene Ltd. (EVGN) | -154.7% | -193.7% | -25.2% |
Evogene Ltd.'s net margin went from -155% (2015) to -194% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -0.08 | -274.68 | -332442.4% |
| Evogene Ltd. (EVGN) | -0.68 | -2.89 | -325.0% |
Evogene Ltd.'s EPS grew from $-0.68 (2015) to $-2.89 (2024).
Chart 5Free Cash Flow — 5 Years
PMGC Holdings Inc. generated $-5M FCF in 2024 (-691% vs 2021). Evogene Ltd. generated $-20M FCF in 2024 (+20% vs 2021).
ELAB vs EVGN: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — ELAB or EVGN?
Over the past 5 years, Evogene Ltd. (EVGN) delivered a total return of -98.2%, compared to -100.0% for PMGC Holdings Inc. (ELAB). A $10,000 investment in EVGN five years ago would be worth approximately $183 today (assuming dividends reinvested). Over 10 years, the gap is even starker: EVGN returned -98.8% versus ELAB's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — ELAB or EVGN?
By beta (market sensitivity over 5 years), Evogene Ltd. (EVGN) is the lower-risk stock at 0.54β versus PMGC Holdings Inc.'s 1.74β — meaning ELAB is approximately 220% more volatile than EVGN relative to the S&P 500.
03Which has better profit margins — ELAB or EVGN?
Evogene Ltd. (EVGN) is the more profitable company, earning -193.7% net margin versus -253.1% for PMGC Holdings Inc. — meaning it keeps -193.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELAB leads at -75.7% versus -255.4% for EVGN. At the gross margin level — before operating expenses — ELAB leads at 72.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — ELAB or EVGN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is ELAB or EVGN better for a retirement portfolio?
For long-horizon retirement investors, Evogene Ltd. (EVGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.54)). PMGC Holdings Inc. (ELAB) carries a higher beta of 1.74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EVGN: -98.8%, ELAB: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between ELAB and EVGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.